pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
IPSEN · news · pharmadog
← back to IPSEN
News mentioning IPSEN
24
stories
14d
Charles River teams up with Ipsen to use virtual control groups in toxicology studies
fiercebiotech
27d
Looking Beyond the First Answer Towards Delivering Impact
fiercebiotech
Sep 30, 26
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
biopharma dive
Sep 28, 26
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
biospace
Sep 23, 26
9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
biopharma dive
Sep 21, 26
STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
stat
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
Aug 20, 26
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
Aug 20, 26
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
biospace
Aug 17, 26
Slate, Fulcrum to combine in reverse merger
biopharma dive
Aug 14, 26
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
Jul 30, 26
Ipsen has 'firepower' for more deals with €2B war chest
endpoints
Jul 24, 26
Ipsen’s Bylvay fails key trial in children with rare liver disease
endpoints
Jul 13, 26
Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial
endpoints
Jul 10, 26
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
biopharma dive
Jul 9, 26
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
endpoints
Jul 7, 26
Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first half
endpoints
Jul 1, 26
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
biopharma dive
Jul 1, 26
STAT+: More signs that GLP-1s may help with peripheral artery disease
stat
Jul 1, 26
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
endpoints
Jun 30, 26
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
biopharma dive
Jun 29, 26
Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
endpoints
Jun 2, 26
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
biopharma dive
Jun 2, 26
Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
endpoints